SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Incyte Reports 71% Response Rate in Phase 1 Colorectal Cancer Trial

Incyte reported a 71% response rate for INCA33890 in combination in a phase 1 colorectal cancer trial.

INCY

Related stories